• AAPL 169.89
  • TSLA 170.18
  • AMZN 173.67
  • MSFT 399.04
  • INTC 35.11
  • EURUSD 1.0731
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. DSKYF.PINK

Daiichi Sankyo Company Limited (DSKYF PINK) stock market data APIs

$31.45 1.15(3.8%) as of April 25, 2024

Daiichi Sankyo Company Limited Financial Data Overview

30.3
31.45
-
31.45
30.17
23.3066-37.3481
59 418 M
49.1905
1 917 M
1 503 471 M
34.69
0.0128
0.293
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'DSKYF',
Type: 'Common Stock',
Name: 'Daiichi Sankyo Company Limited',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
ISIN: NULL,
CUSIP: '23380A109',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'March',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - General',
HomeCategory: 'ADR',
IsDelisted: false,
}

Daiichi Sankyo Company Limited Fundamental Data is available in our Financial Data APIs

  • Net Revenue 1 503 471 M
  • EBITDA 234 585 M
  • Earnings Per Share 0.63
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Daiichi Sankyo Company Limited Earnings via APIs

  • Latest Release 2024-01-30
  • EPS/Forecast 11.85

Get Daiichi Sankyo Company Limited End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Daiichi Sankyo Company Limited latest news via APIs

Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)

Merck MRK announced that a phase II/III study has been initiated on its CDH6-directed DXd antibody-drug conjugate, raludotatug deruxtecan (R-DXd), in patients with platinum-resistant ovarian cancer. ...

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s ENHERTU that showed clinically meaningful responses across a broad range of tumors ENHERTU now has five approved indications with th...
Do you have any questions?
support@eodhistoricaldata.com